CRISPR Therapeutics AG CRSP is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over year.
CRISPR Therapeutics reported quarterly earnings of $9.44 per share, which was up from a loss of $1.30 per share year over year. The company reported quarterly revenue of $900.2 million, which was up from revenue of less than $100,000 year over year.
“We concluded an important quarter in which we reported notable data from our hemoglobinopathies program while rapidly advancing our entire clinical and pre-clinical portfolio and our capabilities,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.
CRISPR Therapeutics is a biotechnology company focused on gene-editing.
Price Action: CRISPR Therapeutics has traded as high as $220.20 and as low as $76.71 over a 52-week period.
At last check Friday, the stock was up 4.20% at $124.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
